Flora Mulkey
About
Flora Mulkey is a scholar working on Oncology, Hematology and Molecular Biology.
According to data from OpenAlex, Flora Mulkey has authored 34 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Flora Mulkey's work include Acute Myeloid Leukemia Research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Statistical Methods in Clinical Trials (6 papers). Flora Mulkey is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Statistical Methods in Clinical Trials (6 papers). Flora Mulkey collaborates with scholars based in United States, Japan and Canada. Flora Mulkey's co-authors include Rajeshwari Sridhara, Roger B. Fillingim, Richard Ohrbach, William Maixner, Joel D. Greenspan, Gary D. Slade, Sirisha L. Mushti, Charles Knott, Eric Bair and Richard Pazdur and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Flora Mulkey
31 papers receiving 1.4k citations
Peers
Flora Mulkey
Mikaël Cohen France
Maria Chiara Gerardi Italy
Tetsu Yamamoto Japan
Joon‐Kee Yoon South Korea
Susanne Koeppen Germany
Uzma Haque United States
István Takács Hungary
Y. Brault France
Kai-Hua Chen China
Kenneth C. Gorson United States
Citations per year, relative to Flora Mulkey Flora Mulkey (= 1×)
peers
Mikaël Cohen
Countries citing papers authored by Flora Mulkey
Since
Specialization
Citations
This map shows the geographic impact of Flora Mulkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flora Mulkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flora Mulkey more than expected).
Fields of papers citing papers by Flora Mulkey
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Flora Mulkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flora Mulkey. The network helps show where Flora Mulkey may publish in the future.
Co-authorship network of co-authors of Flora Mulkey
This figure shows the co-authorship network connecting the top 25 collaborators of Flora Mulkey. A scholar is included among the top collaborators of Flora Mulkey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flora Mulkey. Flora Mulkey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Patel, Jai N., Chen Jiang, Kouros Owzar, et al.. (2024). Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). The Pharmacogenomics Journal. 24(2). 6–6.
2.
Fallah, Jaleh, Flora Mulkey, Mallorie H. Fiero, et al.. (2024). Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies. Journal of Clinical Oncology. 42(32). 3783–3787.
3.
Mushti, Sirisha L., Flora Mulkey, Thomas Gwise, et al.. (2023). Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”. Statistics in Biopharmaceutical Research. 15(2). 315–317.
4.
Voorhees, Peter M., Vera J. Suman, Sascha A. Tuchman, et al.. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202 ). American Journal of Hematology. 96(12). 1595–1603.
5.
Wang, Xin, Flora Mulkey, Xin Gao, et al.. (2021). Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials. Statistics in Biopharmaceutical Research. 15(2). 300–309.
6.
Mushti, Sirisha L., Flora Mulkey, Shenghui Tang, et al.. (2020). Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Current Oncology Reports. 22(11). 116–116.
7.
Xiong, Chenling, Taisei Mushiroda, J Chen, et al.. (2020). Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy. Clinical Pharmacology & Therapeutics. 108(3). 625–634.
8.
Mulkey, Flora, Kunthel By, Marc R. Theoret, et al.. (2019). Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA).. Journal of Clinical Oncology. 37(15_suppl). 2516–2516.
9.
Beaver, Julia A., Maitreyee Hazarika, Flora Mulkey, et al.. (2018). Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 19(2). 229–239.
10.
Norsworthy, Kelly J., Flora Mulkey, Ashley F. Ward, et al.. (2018). Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA). Blood. 132(Supplement 1). 288–288.
11.
Krauss, Aviva C., Flora Mulkey, Amy S. Rosenberg, et al.. (2018). FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.. Journal of Clinical Oncology. 36(15_suppl). 8008–8008.
12.
DeBoer, Rebecca, Flora Mulkey, Meir Wetzler, et al.. (2016). Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia & lymphoma. 57(10). 2298–2306.
13.
Nixon, Andrew B., Alexander B. Sibley, Ace J. Hatch, et al.. (2016). Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. Journal of Clinical Oncology. 34(15_suppl). 3597–3597.
14.
Wetzler, Meir, D. Watson, Wendy Stock, et al.. (2013). Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 99(1). 111–115.
15.
Gupta, Pankaj, Flora Mulkey, Robert P. Hasserjian, et al.. (2013). A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Investigational New Drugs. 31(5). 1311–1320.
16.
Castillo, Jorge J., Flora Mulkey, Susan Geyer, et al.. (2013). Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies. Blood. 122(21). 832–832.
17.
Slade, Gary D., Eric Bair, Kunthel By, et al.. (2011). Study Methods, Recruitment, Sociodemographic Findings, and Demographic Representativeness in the OPPERA Study. Journal of Pain. 12(11). T12–T26.
18.
Greenspan, Joel D., Gary D. Slade, Eric Bair, et al.. (2011). Pain Sensitivity Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case Control Study. Journal of Pain. 12(11). T61–T74.
19.
Ohrbach, Richard, Roger B. Fillingim, Flora Mulkey, et al.. (2011). Clinical Findings and Pain Symptoms as Potential Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control Study. Journal of Pain. 12(11). T27–T45.
20.
Maixner, William, Joel D. Greenspan, Ronald Dubner, et al.. (2011). Potential Autonomic Risk Factors for Chronic TMD: Descriptive Data and Empirically Identified Domains from the OPPERA Case-Control Study. Journal of Pain. 12(11). T75–T91.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mikaël Cohen Breakdown of academic impact, for papers by Maria Chiara Gerardi Breakdown of academic impact, for papers by Tetsu Yamamoto Breakdown of academic impact, for papers by Joon‐Kee Yoon Breakdown of academic impact, for papers by Susanne Koeppen Breakdown of academic impact, for papers by Uzma Haque Breakdown of academic impact, for papers by István Takács Breakdown of academic impact, for papers by Y. Brault Breakdown of academic impact, for papers by Kai-Hua Chen Breakdown of academic impact, for papers by Kenneth C. Gorson